Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,150 | -5,524 | -4,000 | -2,154 | -10,826 |
| Depreciation Amortization | 2 | 2 | 2 | 1 | 56 |
| Accounts payable and accrued liabilities | -404 | -473 | -322 | -337 | -122 |
| Other Working Capital | -138 | -354 | 127 | 74 | -536 |
| Other Operating Activity | 578 | 608 | 405 | 405 | 679 |
| Operating Cash Flow | $-7,112 | $-5,741 | $-3,788 | $-2,011 | $-10,749 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 8 | N/A | N/A | N/A | -5 |
| Investing Cash Flow | $8 | $N/A | $N/A | $N/A | $-5 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,002 | 2,645 | N/A | N/A | 7,452 |
| Common Stock Repurchased | -1 | N/A | N/A | N/A | -11 |
| Other Financing Activity | -5 | -4 | -4 | -4 | -28 |
| Financing Cash Flow | $3,996 | $2,641 | $-4 | $-4 | $7,413 |
| Beginning Cash Position | 8,490 | 8,490 | 8,490 | 8,490 | 11,831 |
| End Cash Position | 5,382 | 5,390 | 4,698 | 6,475 | 8,490 |
| Net Cash Flow | $-3,108 | $-3,100 | $-3,792 | $-2,015 | $-3,341 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,112 | -5,741 | -3,788 | -2,011 | -10,749 |
| Capital Expenditure | -1 | N/A | N/A | N/A | -5 |
| Free Cash Flow | -7,113 | -5,741 | -3,788 | -2,011 | -10,754 |